Top 25 Publications from FY17 Based on Impact Factor

  1. Powers SW; Coffey CS; Chamberlin LA; Ecklund DJ; Klingner EA; Yankey JW; Korbee LL; Porter LL; Hershey AD; Investigators CHAMP. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. The New England journal of medicine. 2017; 376:115-124.
  2. French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nobbout R; Curatolo P; de Vries PJ; Diugos DJ; Berkowitz N. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet. 2016; 388:2153-2163.
  3. Martin KR; Zhou W; Bowman MJ; Shih J; Au KS; Dittenhafer-Reed KE; Sisson KA; Koeman J; Weisenberger DJ; Cottingham SL. The genomic landscape of tuberous sclerosis complex. Nature Communications. 2017; 8:15816.
  4. Glauser TA; Holland K; O'Brien VP; Keddache M; Martin LJ; Clark PO; Cnaan A; Dlugos D; Hirtz DG; Shinnar S. Pharmacogenetics of Antiepileptic Drug Efficacy in Childhood Absence Epilepsy. Annals of Neurology. 2017; 81:444-453.
  5. Augustine EF; Gilbert DL. Clinical pearls and scientific advancement Reconciling tradition with new knowledge. Neurology. 2017; 88:1786-1787.
  6. Sánchez Fernández I; Jackson MC; Abend NS; Arya R; Brenton JN; Carpenter JL; Chapman KE; Gaillard WD; Gaínza-Lein M; Glauser TA. Refractory status epilepticus in children with and without prior epilepsy or status epilepticus. Neurology. 2017; 88:386-394.
  7. Cnaan A; Shinnar S; Arya R; Adamson PC; Clark PO; Dlugos D; Hirtz DG; Masur D; Glauser TA; Study CAE. Second monotherapy in childhood absence epilepsy. Neurology. 2017; 88:182-190.
  8. Payne JM; Barton B; Ullrich NJ; Cantor A; Hearps SJC; Cutter G; Rosser T; Walsh KS; Gioia GA; Wolters PL. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016; 87:2575-2584.
  9. Krueger DA; Wilfong AA; Mays M; Talley CM; Agricola K; Tudor C; Capal J; Holland-Bouley K; Franz DN. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016; 87:2408-2415.
  10. Kang PB; Jr BJF; Mintz M; Joshi SM; Gilbert DL; Radabaugh C; Ruch-Ross H; Pediat AA; Soc CN. The child neurology clinical workforce in 2015: Report of the AAP/CNS Joint Taskforce. Neurology. 2016; 87:1384- 1392.
  11. Blake RB; Gilbert DL; Schapiro MB. Child Neurology: Two sisters with dystonia and regression: PLA2G6-associated neurodegeneration. Neurology. 2016; 87:e1-e3.
  12. López-Juárez A; Titus HE; Silbak SH; Pressler JW; Rizvi TA; Bogard M; Bennett MR; Ciraolo G; Williams MT; Vorhees CV. Oligodendrocyte Nf1 Controls Aberrant Notch Activation and Regulates Myelin Structure and Behavior. Cell Reports. 2017; 19:545-557.
  13. Gross C; Yao X; Engel T; Tiwari D; Xing L; Rowley S; Danielson SW; Thomas KT; Jimenez-Mateos EM; Schroeder LM. MicroRNA-Mediated Downregulation of the Potassium Channel Kv4.2 Contributes to Seizure Onset. Cell Reports. 2016; 17:37-45.
  14. Jin J; Valanejad L; Thuy PN; Lewis K; Wright M; Cast A; Stock L; Timchenko L; Timchenko NA. Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease. Cell Reports. 2016; 16:744-756.
  15. Myer GD; Yuan W; Foss KDB; Thomas S; Smith D; Leach J; Kiefer AW; Dicesare C; Adams J; Gubanich PJ. Analysis of head impact exposure and brain microstructure response in a season-long application of a jugular vein compression collar: a prospective, neuroimaging investigation in American football. British journal of sports medicine. 2016; 50:1276-1285.
  16. Wang ET; Taliaferro JM; Lee JA; Sudhakaran IP; Rossoll W; Gross C; Moss KR; Bassell GJ. Dysregulation of mRNA Localization and Translation in Genetic Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016; 36:11418-11426.
  17. Palomo V; Perez DI; Roca C; Anderson C; Rodríguez-Muela N; Perez C; Morales-Garcia JA; Reyes JA; Campillo NE; Perez-Castillo AM. Subtly Modulating Glycogen Synthase Kinase 3 beta: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry. 2017; 60:4983-5001.
  18. Tajhya RB; Hu X; Tanner MR; Huq R; Kongchan N; Neilson JR; Rodney GG; Horrigan FT; Timchenko LT; Beeton C. Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell death & disease. 2016; 7:e2426-e2426.
  19. Griffis JC; Nenert R; Allendorfer JB; Vannest J; Holland S; Dietz A; Szaflarski JP. The Canonical Semantic Network Supports Residual Language Function in Chronic Post-Stroke Aphasia. Human Brain Mapping. 2017; 38:1636-1658.
  20. Wink LK; Minshawi NF; Shaffer RC; Plawecki MH; Posey DJ; Horn PS; Adams R; Pedapati EV; Schaefer TL; McDougle CJ. D-Cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism. 2017; 8:2.
  21. Kacperski J; Hershey AD. Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. CNS Drugs. 2016; 30:837-844.
  22. Thomson KE; Modi AC; Glauser TA; Rausch JR; White HS. The impact of nonadherence to antiseizure drugs on seizure outcomes in an animal model of epilepsy. Epilepsia. 2017; 58:1054-1062.
  23. Arya R; Wilson JA; Fujiwara H; Rozhkov L; Leach JL; Byars AW; Greiner HM; Vannest J; Buroker J; Milsap G. Presurgical language localization with visual naming associated ECoG high- gamma modulation in pediatric drug-resistant epilepsy. Epilepsia. 2017; 58:663-673.
  24. Skoch J; Adelson PD; Bhatia S; Greiner HM; Rydenhag B; Scavarda D; Mangano FT. Subdural grid and depth electrode monitoring in pediatric patients. Epilepsia. 2017; 58 Suppl 1:56-65.
  25. Vannest J; Tenney JR; Altaye M; Byars AW; Spencer C; Maloney TC; Szaflarski JP; Morita D; Glauser TA. Impact of frequency and lateralization of interictal discharges on neuropsychological and fine motor status in children with benign epilepsy with centrotemporal spikes. Epilepsia. 2016; 57:e161-e167.